<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612454</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1434</org_study_id>
    <secondary_id>2015-001396-40</secondary_id>
    <nct_id>NCT02612454</nct_id>
  </id_info>
  <brief_title>Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to &lt;18 Years of Age With Atopic Dermatitis (AD)</brief_title>
  <official_title>An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to &lt;18 Years of Age With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the long-term safety of dupilumab in&#xD;
      pediatric participants with AD.&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To assess the long-term efficacy of dupilumab in pediatric participants with AD&#xD;
&#xD;
        -  To assess the trough concentrations of functional dupilumab in serum and the&#xD;
           immunogenicity in pediatric participants with AD after re-treatment with dupilumab&#xD;
&#xD;
      Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to &lt;12 years of age with AD&#xD;
&#xD;
      Co-Primary Objectives are:&#xD;
&#xD;
        -  To evaluate the pharmacokinetic (PK) of dupilumab PFPs&#xD;
&#xD;
        -  To evaluate the safety of dupilumab PFPs&#xD;
&#xD;
      Secondary Objective is:&#xD;
&#xD;
      - To evaluate the immunogenicity of dupilumab PFPs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 15, 2015</start_date>
  <completion_date type="Anticipated">November 3, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with at least one TEAE per participant year from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Peak serum concentration after multiple doses of dupilumab administered using the PFP (test) relative to the prefilled syringe (reference)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Drug concentration in serum after multiple doses of dupilumab administered using the PFP (test) relative to the prefilled syringe (reference)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-study</measure>
    <time_frame>Up to week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-study</measure>
    <time_frame>Up to week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent serious adverse events (SAEs) from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs of special interest from baseline through the last study visit</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI from baseline of parent study) response at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EASI score at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in EASI at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Surface Area (BSA) affected by AD (BSA) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at all in-clinic visits post-baseline</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Children's Dermatology Life Quality Index (CDLQI) for participants ≥4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Infants' Dermatology Quality of Life Index (IDQOL) for participants &lt;4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed</measure>
    <time_frame>Baseline up to week 272</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders (defined as participants with IGA 0 or 1) who maintain IGA 0 or 1 during at least 75% of the subsequent* visits during the treatment period</measure>
    <time_frame>Baseline to week 260</time_frame>
    <description>*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For responders (defined as participants with IGA 0 or 1), median percentage of subsequent* visits during the treatment period, at which IGA 0 or 1 is maintained</measure>
    <time_frame>Baseline to week 260</time_frame>
    <description>*Subsequent refers to the visits following the first visit at which IGA 0 or 1 is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AD flares during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualize event rate of AD flares during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with at least one flare during the study</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>AD flares are defined as worsening of the disease that requires escalation/intensification of AD treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of well-controlled weeks</measure>
    <time_frame>Baseline to week 272</time_frame>
    <description>Well-controlled weeks are those for which participants or parents/caregivers answer &quot;Yes&quot; AND during which no rescue treatments were administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPTIONAL SUB-STUDY: Incidence and titer of treatment-emergent anti-drug antibodies (ADA) (PFP Sub-Study)</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Body weight ≥60 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered every two weeks (Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Body weight 30 kg to &lt;60 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered Q2W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Body weight 15 kg to &lt;30 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered every 4 weeks (Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Body weight 5 kg to &lt;15 kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab</intervention_name>
    <description>Weight-tiered dosing administered subcutaneous (SC)</description>
    <arm_group_label>Body weight 15 kg to &lt;30 kg</arm_group_label>
    <arm_group_label>Body weight 30 kg to &lt;60 kg</arm_group_label>
    <arm_group_label>Body weight 5 kg to &lt;15 kg</arm_group_label>
    <arm_group_label>Body weight ≥60 kg</arm_group_label>
    <other_name>DUPIXENT®</other_name>
    <other_name>REGN668</other_name>
    <other_name>SAR231893</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participated in a prior dupilumab study in pediatric participants with AD and&#xD;
             adequately completed the visits and assessments required for both the treatment and&#xD;
             follow-up periods, as defined in the prior study protocol&#xD;
&#xD;
          -  PFP Sub-Study Only:&#xD;
&#xD;
          -  Age ≥2 to &lt;12 years at time of screening&#xD;
&#xD;
          -  Body weight ≥5 kg and &lt;60 kg at time of screening&#xD;
&#xD;
          -  Must have received the same dupilumab dose regimen to be used in the PFP sub-study&#xD;
             during the previous 12 weeks in the main OLE study using the prefilled syringe, as&#xD;
             defined in the protocol&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participants who, during their participation in a prior dupilumab study developed an&#xD;
             adverse event (AE) or serious adverse event (SAE) deemed related to study drug which&#xD;
             could indicate that continued treatment with study drug may present an unreasonable&#xD;
             risk for the patient&#xD;
&#xD;
          -  Participants, who during the participation in a prior Dupilumab study, developed an AE&#xD;
             that was deemed related to study drug and led to study treatment discontinuation,&#xD;
             which in the opinion of the investigator or medical monitor could indicate that&#xD;
             continued treatment with study drug may present an unreasonable risk for the patient&#xD;
&#xD;
          -  Treatment with an investigational drug, other than dupilumab, within 8 weeks or within&#xD;
             5 half-lives (if known), whichever is longer, before the baseline visit&#xD;
&#xD;
          -  Having used immunosuppressive/immunomodulating drugs within 4 weeks before the&#xD;
             baseline visit&#xD;
&#xD;
          -  Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit&#xD;
&#xD;
          -  Diagnosed active endoparasitic infections or at high risk of these infections&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the investigator's judgment, would adversely&#xD;
             affect the participant's participation in the study&#xD;
&#xD;
          -  PFP Sub-study Only:&#xD;
&#xD;
          -  Poor compliance as defined by having missed 1 or more of the planned last 3 injections&#xD;
             in the main OLE study prior to entering the sub-study&#xD;
&#xD;
          -  Switched dupilumab doses within the past 12 weeks&#xD;
&#xD;
          -  Meet criteria for temporary/permanent discontinuation of study drug at time of&#xD;
             screening into PFP sub-study, as defined in the protocol.&#xD;
&#xD;
        Note: Other protocol defined Inclusion / Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>92304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gahanna</city>
        <state>Ohio</state>
        <zip>43230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-3505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 2N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kutna Hora</city>
        <zip>28401</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ústí Nad Labem</city>
        <zip>40113</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Muenster</city>
        <state>North Rhine-Westphal</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Study Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <state>Kielce</state>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Krakow</city>
        <state>Malopolska</state>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kraków</city>
        <state>Malopolska</state>
        <zip>30 363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Białystok</city>
        <zip>15 453</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-065</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-152</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40 611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>30 363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-142</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>91-142</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regeneron Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

